bioRxiv (Cold Spring Harbor Laboratory) · 2023 · 12 citations · 58 references
Life SciencesInfectious DiseasesMedicinal ChemistryMolecular VirologyVaccinologyVirologyAntiviral PharmacologyAntiviral TherapyVaccinationViral Immune EvasionViral InfectionsViral VaccinesCoronavirus VaccinesMiddle East Respiratory Syndrome CoronavirusRna-dependent Rna Polymerase FunctionSars-cov-2 Antiviral ResistanceSars-cov-2 Antiviral TherapySars-cov-2 InfectionTreatment Of Coronavirus InfectionsVaccine-induced Antiviral Immunity
Abstract Despite the wide availability of several safe and effective vaccines that can prevent severe COVID-19 disease, the emergence of SARS-CoV-2 variants of concern (VOC) that can partially evade vaccine immunity remains a global health concern. In addition, the emergence of highly mutated and neutralization-resistant SARS-CoV-2 VOCs such as BA.1 and BA.5 that can partially or fully evade ( 1 ) many therapeutic monoclonal antibodies in clinical use underlines the need for additional effective treatment strategies. Here, we characterize the antiviral activity of GS-5245, Obeldesivir (ODV), an oral prodrug of the parent nucleoside GS-441524, which targets the highly conserved RNA-dependent viral RNA polymerase (RdRp). Importantly, we show that GS-5245 is broadly potent in vitro against alphacoronavirus HCoV-NL63, severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-related Bat-CoV RsSHC014, Middle East Respiratory Syndrome coronavirus (MERS-CoV), SARS-CoV-2 WA/1, and the highly transmissible SARS-CoV-2 BA.1 Omicron variant in vitro and highly effective as antiviral therapy in mouse models of SARS-CoV, SARS-CoV-2 (WA/1), MERS-CoV and Bat-CoV RsSHC014 pathogenesis. In all these models of divergent coronaviruses, we observed protection and/or significant reduction of disease metrics such as weight loss, lung viral replication, acute lung injury, and degradation in pulmonary function in GS-5245-treated mice compared to vehicle controls. Finally, we demonstrate that GS-5245 in combination with the main protease (M pro ) inhibitor nirmatrelvir had increased efficacy in vivo against SARS-CoV-2 compared to each single agent. Altogether, our data supports the continuing clinical evaluation of GS-5245 in humans infected with COVID-19, including as part of a combination antiviral therapy, especially in populations with the most urgent need for more efficacious and durable interventions.
58
Remdesivir for the Treatment of Covid-19 — Final Report
John H. Beigel, Kay M Tomashek, Lori E. Dodd et al. · New England Journal of Medicine · 2020 · 7.7K citations · Full text
Scott M. Hammer, Kathleen Squires, Michael D. Hughes et al. · New England Journal of Medicine · 1997 · 2.7K citations · Full text
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Dora Pinto, Young‐Jun Park, Martina Beltramello et al. · Nature · 2020 · 2.2K citations · Full text